e-therapeutics to present at Shares Evening

RNS Number : 1726P

e-Therapeutics plc

16 February 2021

 

e-therapeutics PLC

e-therapeutics to present at Shares Investor Evening

Oxford, UK, 16 February 2021 -  e-therapeutics plc (AIM: ETX.L, "e-therapeutics" or "the Company")  will be presenting at the Shares Investor Evening - Webinar sponsored by AJ Bell on Wednesday 17^th February 2021. The webinar will start at 18:00 BST and investors can register to attend here :    https://www.sharesmagazine.co.uk/events/event/shares-investor-evening--webinar-170221

Ali Mortazavi, Chairman & CEO of e-therapeutics, will be presenting an overview of the Company and will be available to take questions during the event.

-Ends-

For further information, please contact:

e-therapeutics plc

Ali Mortazavi, Chairman & CEO Tel: [phone]

www.etherapeutics.co.uk

Numis Securities Limited

Freddie Barnfield/Duncan Monteith (Nominated Adviser)

James Black (Corporate Broking)

Tel: [phone]

www.numis.com

About e-therapeutics plc

e-therapeutics plc is an Oxford, UK-based company with a powerful computer-based approach to drug discovery, founded on its industry-leading expertise in network biology to fully capture disease complexity. The Company combines network science, machine learning, artificial intelligence, statistics and big data with expertise in drug discovery and development to transform the search for new medicines and intervention strategies.

e-therapeutics has developed an in silico laboratory that enables the rapid screening of millions of compounds and the identification of small sub-sets that are enriched for highly active hits. Its proprietary platform also has novel applications in functional genomics, being able to analyse complex genetic datasets, provide a deep understanding of pathological mechanisms and distil actionable insights for the discovery of novel drugs, biomarkers and diagnostics.

e-therapeutics has deployed and validated its disease-agnostic drug discovery platform both in house and with partners, including Novo Nordisk, Galapagos NV and a US-based, top 5 pharmaceutical company.

 

END

 

 

NRAUVOBRAWUUAAR